Atlas Trials

Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients

Clinical trial NCT05463224 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05463224
Sponsor
Sehhoon Park
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
NSCLC
Start date
2023-01-04
Primary completion
2026-12-01
Enrollment
150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.